Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

about

Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.

P2860

Q40048109-44787EE4-1C52-4514-AB22-DD4C19006BC7 Q47154849-CACBFD96-18EE-4D85-9B64-069F72F2C82D

P2860

Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

Item

http://www.wikidata.org/entity/Q38897169

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Preclinical immunogenicity and ...... otein-based vaccine candidate.

@en

type

Item

label

Preclinical immunogenicity and ...... otein-based vaccine candidate.

@en

prefLabel

Preclinical immunogenicity and ...... otein-based vaccine candidate.

@en

P1476

Preclinical immunogenicity and ...... rotein-based vaccine candidate

@en

P2093

Ainslie Calcutt

http://www.w3.org/2001/XMLSchema#string

Anne Fane

http://www.w3.org/2001/XMLSchema#string

Catherine M Rush

http://www.w3.org/2001/XMLSchema#string

Davina Gorton

http://www.w3.org/2001/XMLSchema#string

Grace Yeung

http://www.w3.org/2001/XMLSchema#string

Jon Hartas

http://www.w3.org/2001/XMLSchema#string

Linda Johnson

http://www.w3.org/2001/XMLSchema#string

Manisha Pandey

http://www.w3.org/2001/XMLSchema#string

Michael R Batzloff

http://www.w3.org/2001/XMLSchema#string

Tania Rivera-Hernandez

http://www.w3.org/2001/XMLSchema#string

P2860

General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids

Animal models to investigate the pathogenesis of rheumatic heart disease

Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection.

Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain.

Immunogenicity of a 26-valent group A streptococcal vaccine.

Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers.

Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.

T cell mimicry in inflammatory heart disease.

Acute rheumatic fever: a chink in the chain that links the heart to the throat?

B- and T-cell responses in group a streptococcus M-protein- or Peptide-induced experimental carditis.

P304

3089-3096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2016.1222999

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Natkunam Ketheesan

James S McCarthy

Michael F. Good

P577

2016-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27541593

http://www.w3.org/2001/XMLSchema#string

P932

5215552

http://www.w3.org/2001/XMLSchema#string

Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

about

P2860

P2860

Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932